CBT vs ECPG: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
CBT is the larger of the two ($3.64B market cap): the incumbent the market prices for continued execution (9.56x forward earnings, beta 0.82). ECPG is the smaller challenger ($2.28B), cheaper on forward earnings (8.18x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
CBT vs ECPG: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | CBT | ECPG | What it tells you |
|---|---|---|---|
| Market cap | $3.64B | $2.28B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 9.56 | 8.18 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 17.64 | 7.02 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.82 | 1.31 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 35% of range | 78% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 2.23 | 2.12 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: ECPG is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how CBT and ECPG affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CBT and ECPG share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CBT and ECPG exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Cabot Corporation (CBT) do?
Cabot Corporation, based in Boston and founded in 1882, makes the black powder that gives tires their strength and wear resistance. Carbon black is mostly sold through its Reinforcement Materials segment to tire makers such as Michelin, Bridgestone and Goodyear, and that segment produced roughly $599 million of the ~$982 million in sales in the June 2026 quarter. The second segment, Performance Chemicals, sells specialty carbons for plastics and coatings, fumed silica and alumina, inkjet colorants and conductive additives for lithium-ion batteries. Cabot sold its activated carbon (Purification Solutions) unit in 2024 to concentrate on these two businesses, and it runs a global network of plants across the Americas, Europe and Asia, including new capacity in Indonesia and a Mexican carbon black producer bought in early 2026.
What does Encore Capital Group (ECPG) do?
Encore Capital Group is one of the two largest publicly traded buyers of charged-off consumer receivables. When a bank or card issuer gives up on a delinquent account, it sells the paper for cents on the dollar, and Encore is one of the buyers. In the United States it collects through Midland Credit Management (MCM), which handles credit card and consumer loan paper; in Europe, mainly the United Kingdom, it operates as Cabot Credit Management, which buys both unsecured consumer debt and some secured and semi-performing portfolios. The business has three moving parts: how much paper Encore buys and at what price, how much cash it eventually collects against that price, and how cheaply it can fund the balance sheet in between. It reported ~$443.8 million of global portfolio purchases in the second quarter of 2026, split ~$372.3 million in the U.S. (a record) and ~$71.5 million in Europe, and collected ~$736.9 million globally in the same quarter.
CBT vs ECPG: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- CBT drivers: Tire contract pricing and volume recovery; Battery materials and conductive additives.
- ECPG drivers: Supply and purchase pricing in the U.S; Collections converting into recognized revenue.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The biggest risk is that tire pricing keeps resetting lower. For ECPG, the largest single risk is that ERC is a management estimate of cash to be collected over more than a decade, and a downward revision hits both the balance sheet and reported revenue at once, as the ~$101 million goodwill charge attached to weak European results in early 2025 illustrated.
CBT or ECPG: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CBT if you believe its drivers more; ECPG if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CBT and ECPG guides.
CBT vs ECPG: the full fundamentals
CBT. Figures are approximate and tied to the asOf date; verify live numbers before acting. Fiscal 2026 ended September 30 and full-year results are expected in early November 2026, so trailing figures will shift soon. GAAP earnings look far weaker than adjusted earnings this year because of restructuring and benefit plan charges, including a ~$1.55 per share hit in the June quarter. At roughly 12x adjusted earnings the stock trades near specialty chemical peers' low end, and the average analyst target of ~$89 to $91 sits well above the ~$74 quote, after the shares slid from the mid-$80s in August.
ECPG. Q2 2026 produced revenue of ~$491.9 million (up ~11%), GAAP net income of ~$64.0 million and diluted EPS of ~$2.81, which included roughly $1.00 per share of costs from the $1 billion refinancing; adjusted EPS was ~$3.95. Management guided 2026 EPS to ~$13.00 to ~$14.00, which puts the ~$103.68 share price (October 16, 2026) near 7.4 to 8 times guided earnings even after an ~85% rally this year. That multiple is low relative to the broader market for a reason: the earnings depend on multi-year collection estimates and are levered on ~$4.19 billion of debt. The November 4 report (consensus ~$3.35 adjusted EPS) is the next data point.
Headline figures (approximate, October 2026): CBT shows revenue (ttm) ~$3.6 billion (June 2026 quarter ~$982 million, up ~6% year over year), adjusted eps (fy2026 guidance) ~$6.15 to $6.45 vs $7.25 in FY2025; June quarter ~$1.67, segment ebit (june 2026 quarter) Reinforcement Materials ~$97 million (down ~24%); Performance Chemicals ~$68 million (up ~19%), p/e (adjusted, forward) ~12x on FY2026 guidance at a share price near ~$74; ECPG shows revenue (ttm) ~$1.90B, up ~11% in the latest quarter, net income (ttm) ~$302M (net margin ~16%), diluted eps (q2 2026, gaap / adjusted) ~$2.81 / ~$3.95 vs ~$2.62 estimate, 2026 eps guidance ~$13.00 to ~$14.00 (consensus ~$13.52).
The bottom line: CBT vs ECPG
CBT and ECPG are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CBT and ECPG exposure against your real portfolio. It is not an investment adviser.
Wondering how CBT or ECPG fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Cabot Corporation
Ask Walnut's AI anything about CBT and see how it fits what you own.
FAQ
What is the difference between CBT and ECPG?
+
Cabot Corporation, based in Boston and founded in 1882, makes the black powder that gives tires their strength and wear resistance. Encore Capital Group is one of the two largest publicly traded buyers of charged-off consumer receivables. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is CBT or ECPG the better stock?
+
Neither is universally better. CBT is the larger incumbent; ECPG is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, CBT or ECPG?
+
On forward P/E (as of November 2026), CBT trades at 9.56x and ECPG at 8.18x, so ECPG is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both CBT and ECPG?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of CBT vs ECPG?
+
CBT: The biggest risk is that tire pricing keeps resetting lower. Western tire makers face heavy competition from low-cost Asian imports, and if they keep losing share or push Cabot harder in the calendar 2027 contract round, Reinforcement Materials earnings could fall again even with higher volumes. Feedstock is another exposure: carbon black is made from heavy oil residues, and while contracts include pass-through mechanisms, sharp oil swings can squeeze margins for a quarter or two. Cabot runs energy-intensive plants that emit significant CO2, so tighter European carbon pricing and US EPA consent-decree obligations raise compliance costs. Battery materials face fierce price competition from Chinese nanotube makers and depend on an electric vehicle market that has slowed in the West. Restructuring brings execution risk, and the Botlek closures still need local approval. A CEO transition adds strategic uncertainty, the former CEO sold about 25% of his stake in August, and Cabot's large operations in China, Indonesia and Latin America expose it to currency moves, tariffs and geopolitical disruption. Finally, analyst consensus sits at Hold, with targets clustered near the current price. ECPG: The largest single risk is that ERC is a management estimate of cash to be collected over more than a decade, and a downward revision hits both the balance sheet and reported revenue at once, as the ~$101 million goodwill charge attached to weak European results in early 2025 illustrated. Leverage magnifies everything: ~$4.18 billion of borrowings against a ~$2.2 billion equity value (a debt-to-equity ratio near 388%) means a modest miss on collections or a jump in refinancing rates can move equity value sharply. Regulation is a standing exposure rather than a one-time event, since Encore operates under a history of CFPB enforcement in the U.S. (a 2015 consent order and a 2020 settlement) plus Reg F, the FDCPA, state licensing regimes, and FCA supervision of Cabot in the U.K., and any of those can raise compliance cost or restrict collection methods. Competition for portfolios is the quiet risk, because too much capital chasing the same paper raises purchase prices and depresses returns that will not be visible for several years. After an ~85% gain in 2026, a smaller margin of safety also sits in the share price than when the stock traded in the $40s a year ago. A consumer environment that improves sharply would also cut the supply of charged-off paper, while one that deteriorates too far can lift purchase volumes and slow the pace at which people actually pay.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CBT or ECPG; figures are approximate and dated (as of November 2026). Verify current data before investing.